Interaksi Eksenatid

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (label Flukonazol, Interaksi obat)

This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. (label Glipizid dan metformin, Kontraindikasi)

Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, including BYETTA [see Adverse Reactions (6.2) ] . (label Eksenatid, Peringatan dan perhatian)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (label Hidroksiklorokuin, Peringatan dan perhatian)

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (label Klorokuin, Peringatan)

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (label Siprofloksasin, Interaksi obat)

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (label Abirateron, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (label Amlodipin dan benazepril, Interaksi obat)

Consideration should be taken in patients being treated with antidiabetic agents. (label Asetazolamid, Interaksi obat)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (label Asitretin, Interaksi obat)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (label Aspirin dan dipiridamol, Interaksi obat)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (label Atazanavir, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (label Benazepril, Interaksi obat)

Antidiabetic agents: Dosage adjustment of antidiabetic drug may be required. (label Benazepril dan hidroklorotiazid, Interaksi obat)

However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (label Bisoprolol, Peringatan)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (label Bisoprolol dan hidroklorotiazid, Perhatian)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (label Brimonidin dan timolol, Peringatan dan perhatian)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (label Butalbital, aspirin, dan kafein, Interaksi obat)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (label Butalbital, aspirin, kafein, dan kodein, Interaksi obat)

Caution should be exercised when used with antidiabetic drugs. (label Danazol, Interaksi obat)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (label Darunavir, Peringatan dan perhatian)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (label Darunavir dan kobisistat, Peringatan dan perhatian)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (label Deksametason, Peringatan dan perhatian)

Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (label Digoksin, Interaksi obat)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (label Dorzolamid dan timolol, Peringatan dan perhatian)

Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with BYETTA [see Adverse Reactions (6.2) ] . (label Eksenatid, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. (label Enalapril dan hidroklorotiazid, Perhatian)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (label Fentermin, Peringatan dan perhatian)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (label Fludrokortison, Interaksi obat)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (label Fluoksetin, Peringatan dan perhatian)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (label Fosamprenavir, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (label Hidroklorotiazid, Interaksi obat)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (label Hidrokortison, Interaksi obat)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Irbesartan dan hidroklorotiazid, Interaksi obat)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (label Itrakonazol, Interaksi obat)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

Antidiabetic drugs (oral agents and insulin) − Dosage adjustment of the antidiabetic drug may be required. (label Kandesartan dan hidroklorotiazid, Interaksi obat)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (label Kapesitabin, Interaksi obat)

Insulin and oral hypoglycemics action may be enhanced. (label Karvedilol, Interaksi obat)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (label Ketokonazol, Interaksi obat)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (label Klaritromisin, Peringatan dan perhatian)

Antidiabetic Drugs (Oral Agents and Insulin) - dosage adjustment of the antidiabetic drug may be required. (label Klorotiazid, Interaksi obat)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (label Lanreotid, Peringatan dan perhatian)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (label Levofloksasin, Peringatan dan perhatian)

Worsening of Diabetic Control : May worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (label Levotiroksin, Peringatan dan perhatian)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (label Levotiroksin dan liotironin, Interaksi obat)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (label Linezolid, Peringatan dan perhatian)

• Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (label Liotironin, Peringatan dan perhatian)

Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with BYETTA [see Adverse Reactions (6.2) ] . (label Eksenatid, Peringatan dan perhatian)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (label Lisinopril, Interaksi obat)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (label Lisinopril dan hidroklorotiazid, Interaksi obat)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (label Lopinavir dan ritonavir, Peringatan dan perhatian)

Antidiabetic drugs: dosage adjustment of antidiabetic may be required. (label Losartan dan hidroklorotiazid, Interaksi obat)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (label Metilprednisolon, Interaksi obat)

Insulin And Oral Antidiabetic Agents See Glucose Tolerance under PRECAUTIONS , General . (label Metolazon, Interaksi obat)

Antidiabetic drugs: Dosage adjustment may be required. (label Metoprolol dan hidroklorotiazid, Interaksi obat)

Antidiabetic agents Carefully monitor blood glucose. (label Moksifloksasin, Interaksi obat)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (label Nadolol, Peringatan)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (label Naltrekson dan bupropion, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (label Ofloksasin, Peringatan)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (label Oktreotid, Peringatan dan perhatian)

• Antidiabetic drugs: Dosage adjustment may be required. (label Olmesartan dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (label Orlistat, Peringatan dan perhatian)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (label Pindolol, Peringatan)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (label Prednisolon, Interaksi obat)

Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (label Pregabalin, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

Decrease exposure Digitoxin Decrease exposure Fluoroquinolones Pefloxacin Administered with rifampin 900 mg daily Decrease exposure Moxifloxacin , Decrease exposure Oral Hypoglycemic Agents (e.g., sulfonylureas) Glyburide Decrease exposure Rifampin may worsen glucose control of glyburide. (label Rifampisin, Interaksi obat)

…Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines… (label Rifapentin, Interaksi obat)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (label Ritonavir, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (label Salsalat, Interaksi obat)

Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with BYETTA [see Adverse Reactions (6.2) ] . (label Eksenatid, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (label Eksenatid, Peringatan dan perhatian)

The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (label Somatropin, Peringatan dan perhatian)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (label Sotalol, Interaksi obat)

Antidiabetic drugs (e.g., oral agents, insulin): Dosage adjustment of the antidiabetic drug may be required (see Precautions ). (label Spironolakton dan hidroklorotiazid, Interaksi obat)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (label Sulfametoksazol dan trimetoprim (kotrimoksazol), Interaksi obat)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (label Sunitinib, Peringatan dan perhatian)

Antidiabetic drugs: Dosage adjustment may be required ( 7.6 ) (label Telmisartan dan hidroklorotiazid, Interaksi obat)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (label Temsirolimus, Peringatan dan perhatian)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (label Timolol, Peringatan dan perhatian)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (label Eksenatid, Peringatan dan perhatian)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (label Trandolapril, Interaksi obat)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (label Tranilsipromin, Peringatan dan perhatian)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (label Triamsinolon, Interaksi obat)

Dyrenium (triamterene) may raise blood glucose levels; for adult-onset diabetes, dosage adjustments of hypoglycemic agents may be necessary during and/or after therapy; concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (label Triamteren, Interaksi obat)

Oral Hypoglycemic Drugs Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (label Triamteren dan hidroklorotiazid, Interaksi obat)

Hydrochlorothiazide: When administered concurrently, the following drugs may interact with thiazide diuretics: Antidiabetic Drugs (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required. (label Valsartan dan hidroklorotiazid, Interaksi obat)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (label Vorikonazol, Interaksi obat)

• Warfarin: Postmarketing reports of increased INR sometimes associated with bleeding. (label Eksenatid, Interaksi obat)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (label Bupropion, Peringatan dan perhatian)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (label Eksenatid, Interaksi obat)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (label Eksenatid, Interaksi obat)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (label Eksenatid, Interaksi obat)

For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. (label Eksenatid, Interaksi obat)

Antidiabetic drug requirements (i.e., insulin) may be altered. (label Dietilpropion, Interaksi obat)

For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. (label Eksenatid, Interaksi obat)

For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. (label Eksenatid, Interaksi obat)

For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. (label Eksenatid, Interaksi obat)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (label Fendimetrazin, Interaksi obat)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (label Eksenatid, Interaksi obat)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (label Klozapin, Peringatan dan perhatian)

For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. (label Eksenatid, Interaksi obat)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (label Lovastatin, Interaksi obat)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (label Mikonazol, Interaksi obat)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (label Moeksipril, Interaksi obat)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (label Nifedipin, Perhatian)

For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. (label Eksenatid, Interaksi obat)

For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. (label Eksenatid, Interaksi obat)

For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. (label Eksenatid, Interaksi obat)

For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. (label Eksenatid, Interaksi obat)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (label Eksenatid, Interaksi obat)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (label Eksenatid, Interaksi obat)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (label Eksenatid, Interaksi obat)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (label Eksenatid, Interaksi obat)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (label Sulfadiazin, Interaksi obat)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (label Telmisartan dan amlodipin, Interaksi obat)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (label Tolmetin, Interaksi obat)

Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. (label Eksenatid, Interaksi obat)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (label Ziprasidon, Peringatan dan perhatian)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (label Sulindak, Interaksi obat)